Class-action law firm urges MGNX investors who have suffered losses of $50K+ to submit your loss now to learn if they qualify to recover their investment losses.
SAN FRANCISCO, Oct. 22, 2019 (GLOBE NEWSWIRE) — Hagens Berman Sobol Shapiro LLP reminds investors in MacroGenics (MGNX) of the securities fraud class action filed against the company and urges MGNX investors who have suffered losses in excess of $50,000 to contact the firm.
Class Period: Feb. 6, 2019 – June 3, 2019
Lead Plaintiff Deadline: Nov. 12, 2019
Sign Up: https://www.hbsslaw.com/investor-fraud/mgnx
Contact An Attorney Now: [email protected]
MGNX Securities Class Action:
According to the Complaint, Defendants concealed adverse information obtained during MacroGenics’ clinical trial evaluating Margetuximab, a potential breast cancer treatment. Specifically, as early as October 2018, Defendants knew but omitted to disclose that (1) the progression-free survival (“PFS”) of patients in the trial was negligible, and (2) the overall survival (“OS”) was not statistically significant. The market learned the truth on June 4, 2019, when MacroGenics disclosed the lackluster PFS and OS results. This news drove the price of MGNX shares sharply lower that day.
If you invested in MacroGenics between Feb. 6, 2019 and June 3, 2019 and suffered significant losses (in excess of $50,000) you may qualify to be a lead plaintiff – one who selects and oversees the attorneys prosecuting the case. Contact Hagens Berman immediately to obtain additional information about this case or being a lead plaintiff.
“We are focused on investors’ losses and the extent to which Defendants’ statements may have been misleading,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding MacroGenics should consider their options to help in the investigation or take advantage of the SEC whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Reed Kathrein, 510-725-3000
- CytomX Investors: Last Days to Seek Participation in Class Action as Lead Plaintiff - July 12, 2020
- Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress - July 12, 2020
- AMAG Announces Presentation of Ciraparantag Data at the International Society on Thrombosis and Haemostasis - July 12, 2020